Potential roles of ellagic acid on metabolic variables in diabetes mellitus : A systematic review
Abstract Diabetes mellitus is a widespread endocrine disorder globally. Due to its antioxidant and anti‐inflammatory properties, ellagic acid has the potential to improve the metabolic effects of chronic non‐communicable diseases. This systematic review summarizes current evidence about the potential effects of ellagic acid on metabolic variables in diabetes mellitus. A comprehensive systematic literature search was conducted in databases such as PubMed, Scopus, EMBASE, ProQuest and Google Scholar from inception until March 2022. All animal studies and clinical trials were eligible for inclusion. Studies using in vitro models or published in a non‐English language were excluded. Of 1320 articles, 23 were selected for assessment, including 21 animal studies and two randomized controlled trial studies. Following ellagic acid administration, findings reported improvement in FBS, HbA1c, insulin (20, 8 and 12 studies, respectively), TG, TC, HDL‐C (13, 10 and 5 studies, respectively), MDA, GSH, CAT, SOD (11, 6, 3 and 4 studies, respectively), and TNF‐α and IL‐6 (6 and 3 studies, respectively). In conclusion, ellagic acid may improve glycaemic indicators, dyslipidaemia, oxidative stress and inflammation in diabetes mellitus. However, further clinical trials are needed to explore the mechanisms more precisely and to observe the applied consequences..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Clinical and Experimental Pharmacology and Physiology - 50(2023), 2, Seite 121-131 |
| Beteiligte Personen: |
Maleki, Vahid [VerfasserIn] |
|---|
| Anmerkungen: |
© 2023 John Wiley & Sons Australia, Ltd. |
|---|
| Umfang: |
11 |
|---|
| doi: |
10.1111/1440-1681.13729 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY003390764 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY003390764 | ||
| 003 | DE-627 | ||
| 005 | 20231111135424.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230213s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/1440-1681.13729 |2 doi | |
| 028 | 5 | 2 | |a 2023-11-11_CEP_2023_50_2.zip.xml |
| 035 | |a (DE-627)WLY003390764 | ||
| 035 | |a (WILEY)CEP13729 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Maleki, Vahid |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potential roles of ellagic acid on metabolic variables in diabetes mellitus |b A systematic review |
| 264 | 1 | |c 2023 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 John Wiley & Sons Australia, Ltd. | ||
| 520 | |a Abstract Diabetes mellitus is a widespread endocrine disorder globally. Due to its antioxidant and anti‐inflammatory properties, ellagic acid has the potential to improve the metabolic effects of chronic non‐communicable diseases. This systematic review summarizes current evidence about the potential effects of ellagic acid on metabolic variables in diabetes mellitus. A comprehensive systematic literature search was conducted in databases such as PubMed, Scopus, EMBASE, ProQuest and Google Scholar from inception until March 2022. All animal studies and clinical trials were eligible for inclusion. Studies using in vitro models or published in a non‐English language were excluded. Of 1320 articles, 23 were selected for assessment, including 21 animal studies and two randomized controlled trial studies. Following ellagic acid administration, findings reported improvement in FBS, HbA1c, insulin (20, 8 and 12 studies, respectively), TG, TC, HDL‐C (13, 10 and 5 studies, respectively), MDA, GSH, CAT, SOD (11, 6, 3 and 4 studies, respectively), and TNF‐α and IL‐6 (6 and 3 studies, respectively). In conclusion, ellagic acid may improve glycaemic indicators, dyslipidaemia, oxidative stress and inflammation in diabetes mellitus. However, further clinical trials are needed to explore the mechanisms more precisely and to observe the applied consequences. | ||
| 700 | 1 | |a Abbaszadeh, Sepideh |4 aut | |
| 700 | 1 | |a Seyyed Shoura, Seyyed Morteza |4 aut | |
| 700 | 1 | |a Sohrabnavi, Asma |4 aut | |
| 700 | 1 | |a Sepandi, Mojtaba |4 aut | |
| 700 | 1 | |a Taghdir, Maryam |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and Experimental Pharmacology and Physiology |g 50(2023), 2, Seite 121-131 |w (DE-627)WLY003385043 |x 14401681 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2023 |g number:2 |g pages:121-131 |g extent:11 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2023 |e 2 |h 121-131 |g 11 | ||